Clinical Report: The Bausch + Lomb TENEO Excimer Laser Platform in LASIK
Overview
The Bausch + Lomb TENEO Excimer Laser Platform represents a significant advancement in LASIK technology, offering improved speed, efficiency, and safety. Clinical trials demonstrated superior patient outcomes, including a manifest refractive spherical equivalent of -0.04 D at 9 months for treated eyes.
Background
The introduction of the TENEO platform marks the first FDA approval of an excimer laser for LASIK in 17 years, highlighting the ongoing evolution of refractive surgery. Enhanced features such as a high-speed laser and an internal nomogram aim to reduce errors and improve patient comfort. Understanding these advancements is crucial for optimizing LASIK outcomes and patient satisfaction.
Data Highlights
| Parameter | Value |
|---|---|
| Manifest Refractive Spherical Equivalent | -0.04 D |
| Number of Eyes Treated | 333 |
| Ablation Time | 1.2 seconds per diopter |
| Eye Tracker Frequency | 1,740 times per second |
Key Findings
- TENEO is the first excimer laser platform approved by the FDA in 17 years.
- It features a high-speed laser operating at 500 Hz, allowing for rapid treatments.
- The internal nomogram eliminates manual calculation errors, enhancing efficiency.
- Clinical trials showed improved visual outcomes compared to traditional glasses or contact lenses.
- Patient comfort is prioritized with an adjustable microscope and a specially designed bed.
Clinical Implications
Surgeons should consider the TENEO platform for its advanced features that enhance LASIK procedure efficiency and patient comfort. The improved outcomes reported in clinical trials suggest that patients may experience greater satisfaction and visual acuity post-surgery.
Conclusion
The Bausch + Lomb TENEO Excimer Laser Platform represents a notable advancement in LASIK technology, with promising clinical outcomes that may redefine patient expectations and satisfaction in refractive surgery.
References
- George O. Waring IV, MD, FACS, Philip Roholt, MD, Ophthalmology Management, 2025 -- The Bausch + Lomb TENEO Excimer Laser Platform: A Big Small Step Forward in LASIK
- Ophthalmology Management, 2025 -- Spotlight on Technology & Technique: A New Addition to the Excimer Family
- AAO, 2024 -- SUMMARY BENCHMARKS FOR PREFERRED PRACTICE
- Ophthalmology Management — The Bausch + Lomb TENEO Excimer Laser Platform: A Big Small Step Forward in LASIK
- ophthalmology management — Spotlight on Technology & Technique: A New Addition to the Excimer Family
- Ophthalmology Management — Spotlight on Technology & Technique: A New Addition to the Excimer Family
- SUMMARY BENCHMARKS FOR PREFERRED PRACTICE
- Laser in Situ Keratomileusis Outcomes and Complications: 2016 to 2023 - PubMed
- P990027.S021.SSED.11.22.2023.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.